Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVAC NASDAQ:MRUS NASDAQ:PCVX NASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVACCureVac$5.41+0.4%$5.17$2.37▼$5.72$1.21B2.53838,251 shs516,327 shsMRUSMerus$65.56-1.0%$56.89$33.19▼$67.59$4.58B1.09679,176 shs664,677 shsPCVXVaxcyte$33.02-2.7%$34.44$27.66▼$121.06$4.38B1.211.17 million shs1.11 million shsTLXTelix Pharmaceuticals$13.05-4.0%$16.05$12.90▼$30.36$4.60BN/A56,084 shs55,378 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVACCureVac+0.37%-0.92%+0.19%+51.97%+43.50%MRUSMerus-1.03%-1.89%+22.93%+48.36%+23.60%PCVXVaxcyte-2.74%-9.86%-0.75%-6.70%-58.14%TLXTelix Pharmaceuticals-3.97%-8.10%-20.91%-30.21%+1,304,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVACCureVac4.4438 of 5 stars4.13.00.04.92.70.01.3MRUSMerus2.9208 of 5 stars3.54.00.00.02.72.50.0PCVXVaxcyte2.2389 of 5 stars3.62.00.00.03.01.70.0TLXTelix PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVACCureVac 2.20Hold$6.8326.31% UpsideMRUSMerus 3.00Buy$86.4031.79% UpsidePCVXVaxcyte 3.10Buy$136.50313.39% UpsideTLXTelix Pharmaceuticals 3.00Buy$22.3371.14% UpsideCurrent Analyst Ratings BreakdownLatest CVAC, TLX, PCVX, and MRUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025TLXTelix PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform7/3/2025TLXTelix PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.006/26/2025CVACCureVacUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Neutral$12.00 ➝ $5.506/13/2025CVACCureVacJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$7.00 ➝ $5.006/12/2025CVACCureVacCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform6/12/2025CVACCureVacCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/12/2025TLXTelix PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$22.006/5/2025TLXTelix PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$22.005/28/2025CVACCureVacJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$10.005/23/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$96.00 ➝ $110.005/19/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVACCureVac$579.18M2.10$0.88 per share6.17$3.36 per share1.61MRUSMerus$36.13M125.59N/AN/A$9.46 per share6.93PCVXVaxcyteN/AN/AN/AN/A$26.52 per shareN/ATLXTelix Pharmaceuticals$516.72M8.55$0.11 per share119.01$1.12 per share11.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVACCureVac$175.50M$0.925.88N/AN/A35.44%30.89%25.54%8/13/2025 (Estimated)MRUSMerus-$215.33M-$4.08N/AN/AN/A-506.73%-35.99%-29.83%8/7/2025 (Estimated)PCVXVaxcyte-$463.93M-$3.99N/AN/AN/AN/A-17.12%-16.26%8/5/2025 (Estimated)TLXTelix Pharmaceuticals$32.93MN/A0.0027.19N/AN/AN/AN/A8/20/2025 (Estimated)Latest CVAC, TLX, PCVX, and MRUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/20/2025H1 2025TLXTelix Pharmaceuticals$0.2160N/AN/AN/A$316.69 millionN/A8/13/2025Q2 2025CVACCureVac-$0.15N/AN/AN/A$4.27 millionN/A8/7/2025Q1 2025MRUSMerus-$1.17N/AN/AN/AN/AN/A8/5/2025Q2 2025PCVXVaxcyte-$1.12N/AN/AN/AN/AN/A5/22/2025Q1 2025CVACCureVac-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million5/14/2025Q1 2025MRUSMerus-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million5/14/2025Q1 2025PCVXVaxcyte-$1.02-$1.04-$0.02-$1.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVACCureVacN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVACCureVac0.057.657.64MRUSMerusN/A5.865.86PCVXVaxcyteN/A17.7017.70TLXTelix Pharmaceuticals0.992.782.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVACCureVac17.26%MRUSMerus96.14%PCVXVaxcyte96.78%TLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCVACCureVac2.15%MRUSMerus4.57%PCVXVaxcyte3.10%TLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVACCureVac880224.34 million219.52 millionOptionableMRUSMerus3769.21 million66.05 millionOptionablePCVXVaxcyte160129.00 million125.01 millionOptionableTLXTelix PharmaceuticalsN/A338.40 millionN/AN/ACVAC, TLX, PCVX, and MRUS HeadlinesRecent News About These CompaniesTLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law FirmJuly 31 at 2:19 PM | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLXJuly 31 at 10:00 AM | prnewswire.comTelix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens BermanJuly 31 at 9:20 AM | prnewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Reaches New 1-Year Low - Should You Sell?July 30 at 12:40 PM | marketbeat.comTelix H1 2025 Results: Investor Webcast NotificationJuly 29, 2025 | globenewswire.comTelix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens BermanJuly 29, 2025 | globenewswire.comTelix Pharmaceuticals: Assessing The Market's Pullback On SEC InquiryJuly 29, 2025 | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLXJuly 28, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLXJuly 27, 2025 | prnewswire.comWilliam Blair Issues Optimistic Forecast for TLX EarningsJuly 26, 2025 | americanbankingnews.comTelix Pharmaceuticals (NASDAQ:TLX) Sees Strong Trading Volume - What's Next?July 25, 2025 | marketbeat.comTelix Pharmaceuticals Limited (TLX) Investors Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationJuly 24, 2025 | tmcnet.comSecurities Fraud Investigation Into Telix Pharmaceuticals Limited (TLX) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law FirmJuly 24, 2025 | businesswire.comTelix Pharmaceuticals Limited (TLX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationJuly 24, 2025 | businesswire.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's WhyJuly 24, 2025 | marketbeat.comEquities Analysts Offer Predictions for TLX FY2025 EarningsJuly 24, 2025 | marketbeat.comINVESTOR ALERT: Investigation of Telix Pharmaceuticals Limited (TLX) Announced by Holzer & Holzer, LLCJuly 23, 2025 | globenewswire.comSecurities Fraud Investigation Into Telix Pharmaceuticals Limited (TLX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. CruzJuly 23, 2025 | businesswire.comTelix Pharmaceuticals stock drops as SEC probes disclosures tied to cancer treatmentJuly 23, 2025 | msn.comTelix sinks as US regulator SEC issues subpoena over claimsJuly 23, 2025 | msn.comWhy did the Telix share price just crash 16%?July 23, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVAC, TLX, PCVX, and MRUS Company DescriptionsCureVac NASDAQ:CVAC$5.41 +0.02 (+0.37%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$5.40 -0.02 (-0.28%) As of 08/1/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Merus NASDAQ:MRUS$65.56 -0.68 (-1.03%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$65.50 -0.06 (-0.08%) As of 08/1/2025 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Vaxcyte NASDAQ:PCVX$33.02 -0.93 (-2.74%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$32.91 -0.11 (-0.33%) As of 08/1/2025 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Telix Pharmaceuticals NASDAQ:TLX$13.05 -0.54 (-3.97%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$13.05 0.00 (0.00%) As of 08/1/2025 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
